Volastra Therapeutics
- Founded: 2020
- Location: New York, NY
- Employee range: 11 - 50
- Clinical stage: Clin1
- Therapy area: Multiple cancers
- Drug types: ONC
- Lead product: Sovilnesib
- Product link: https://www.volastratx.com/pipeline/
- Funding: $60M A Mar 2023; $32M seed Apr 2021; $12M seed Sep 2020
- Investors: Vida Ventures, Catalio Capital Management, Polaris Partners, Droia Ventures, Arch Venture Partners, Quark Venture, Cornell University
volastratx.com linkedin.com job board
Short description:
Therapies for the treatment of metastatic cancers
Drug notes:
VLS-1488 Clin0 oncology; 2 undisclosed programs RD oncology
Long description:
Volastra Therapeutics is developing drugs that target a vulnerability of cancer cells - chromosomal instability, or CIN. CIN is present in 60-80% of cancers and is associated with poor survival in many patients. By using their proprietary CINtech platform that incorporates cancer biology, data sciences and medicinal chemistry, Volastra is turning a deep biological understanding of CIN into life-saving therapies. The tools Volastra is using range from CIN CRISPR screen, CIN imaging and genomics to molecular structure-activity analysis. Volastra is initially focusing on two therapeutic approaches: synthetic lethality and immune activation, with programs in early development.
© 2024 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com